PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

Recruiting

Phase 2

PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationPB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

Sponsor:

Mayo Clinic

Code:

NCT05190744

Conditions

Autosomal Dominant Polycystic Kidney Disease

Nephrogenic Diabetes Insipidus

Acquired Nephrogenic Diabetes Insipidus

Congenital Nephrogenic Diabetes Insipidus

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2024-04-22.